Contact Us: Sales@finabio.com

Now Available: Affordable CRM197 and TTHc

 

EcoCRM™, economical CRM from E. coli, will significantly reduce the cost of conjugate vaccines.

CRM197, a genetically detoxified diphtheria toxin, is widely used as a carrier protein in conjugate vaccines. Effective conjugate vaccines against Streptococcus pneumonaie, Haemophilus influenzae b and Neisseria meningitidis have been made using this carrier protein. Fina BioSolutions has developed a highly efficient Escherichia coli expression system for CRM197, along with a simple purification scheme.  We express soluble, properly folded CRM197 in the cytoplasm of E.coli and achieve expression yields of grams per liter.


Pricing
For Pricing, please contact: Sales@finabio.com


CRM Biophysics Poster FinaBio
download

To view or download the poster, click here.


CRM Biophysics Poster FinaBio
download

To view or download the poster, click here.

 

Recombinant Tetanus Toxin Heavy Chain Fragment C

(rTTHc)

Tetanus toxoid (TT) is frequently used as the carrier protein for conjugate vaccines, in addition to being a component of the DPT vaccine. TT contains very strong T cell epitopes. However, as a toxoided protein, many of the surface lysines are blocked by the toxoiding process. TT is not a uniform product. Each manufacturer has its own specific toxoiding and purification process. Tetanus tends to aggregate with age. Furthermore, TT is not generally affordable in the quantities needed for research and early clinical work.

Tetanus toxoid heavy chain fragment C (TTHc) is the C terminal fragment of the toxin. It is devoid of the toxin’s enzymatic activity but contains the binding site necessary for uptake of the toxin by neurons. Significantly, the majority of the antibody response to tetanus toxoid is against epitopes contained within TTHc.   Fragment C contains the powerful T cell epitopes of tetanus toxin without the toxicity.

Fina Biosolutions now offers recombinant TTHc (rTTHc), combining the advantages of the toxoid with the reproducibility of a recombinant protein. FinaBio expresses rTTHc as a properly folded, soluble protein in E. coli cytoplasm.


Pricing
For additional information and pPricing, please contact: Sales@finabio.com


 

sec-hplctthc

News

  • About FinaBio
    Whitepaper
    Characterization of Fina Biosolutions’ Amino-Dextran
  • About FinaBio

Address

9430 Key West Ave., Suite 200
Rockville, MD 20850
877-346-2246 (877-FinaBio)
301-633-0464 (Andrew Lees, Scientific Director)
Finabio.net
ALees@FinaBio.com

About Us

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.